Haemonetics
HAE
Market cap $3.94B

78.40 USD

+0.32

0.41%

At close Jan 2, 4:00 PM EST

After hours

78.40

+0.00

0.00%

1 day

0.41%

5 days

1.98%

1 month

-10.38%

3 months

-1.15%

6 months

-5.61%

Year to date

-7.92%

1 year

-7.92%

5 years

-31.99%

10 years

112.35%

About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Employees: 3,657

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,812 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

123% more call options, than puts

Call options by funds: $47.1M | Put options by funds: $21.1M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

4% less capital invested

Capital invested by funds: $4.67B [Q2] → $4.46B (-$208M) [Q3]

7% less repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 112

2.24% less ownership

Funds ownership: 110.74% [Q2] → 108.5% (-2.24%) [Q3]

4% less funds holding

Funds holding: 316 [Q2] → 302 (-14) [Q3]

24% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 59

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$108

38%

upside

Avg. target

$114

45%

upside

High target

$120

53%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

JP Morgan Rohin Patel 0% 1-year accuracy 0 / 1 met price target	48%upside $116	Overweight Initiated	6 Dec 2024
Barrington Research Michael Petusky 34% 1-year accuracy 23 / 67 met price target	38%upside $108	Outperform Maintained	4 Dec 2024
Needham Mike Matson 51% 1-year accuracy 59 / 116 met price target	43%upside $112	Buy Reiterated	3 Dec 2024
Raymond James Andrew Cooper 17% 1-year accuracy 2 / 12 met price target	53%upside $120	Strong Buy Upgraded	8 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about HAE published over the past 30 days

Zacks Investment Research

5 Beaten-Down MedTech Stocks Set to Rebound in 2025

Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.

5 Beaten-Down MedTech Stocks Set to Rebound in 2025

Zacks Investment Research

Here's Why You Should Add HAE Stock to Your Portfolio Now

Strong prospects for the Plasma franchise and favorable solvency bode well for Haemonetics.

Here's Why You Should Add HAE Stock to Your Portfolio Now

Zacks Investment Research

Down -11.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Haemonetics (HAE)

The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -11.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Haemonetics (HAE)

Zacks Investment Research

HAE or SYK: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?

HAE or SYK: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Are Investors Undervaluing Haemonetics (HAE) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Haemonetics (HAE) Right Now?

Zacks Investment Research

Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 27.8% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High?

Zacks Investment Research

Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?

Haemonetics inks a new agreement to sell its whole blood assets to GVS. The transaction is expected to be closed in the first quarter of 2025.

Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?

Zacks Investment Research

4 Medical Product Stocks to Buy From a Prospective Industry

An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.

4 Medical Product Stocks to Buy From a Prospective Industry

Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A

BOSTON , Dec. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. The transaction comprises a total cash consideration of up to $67.1M, which includes $44.6M upfront and up to $22.5M in contingent earn-outs over the next four years.

Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A

Zacks Investment Research

HAE or BSX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?

HAE or BSX: Which Is the Better Value Stock Right Now?

See News Rankings

Charts implemented using Lightweight Charts™